Latest News Archive

Please select Category, Year, and then Month to display items

UFS resumes training of undergraduate students at Pelonomi Hospital in Bloemfontein

10 June 2019 | Story Lacea Loader

The executive committee of the University of the Free State (UFS) has today resumed the training of its undergraduate students in the School of Clinical Medicine at the Pelonomi Hospital in Bloemfontein with immediate effect.

The decision to suspend the training of undergraduate students at the hospital came after the attempted rape of a medical intern last week, as well as the robbery of a medical officer in the parking area of the hospital over the weekend.

This morning, discussions involving the university management, the Head of the Department of Health (DoH) in the Free State Province, the executive committee of the Pelonomi Hospital, and the South African Police Service (SAPS) took place regarding the security situation at the hospital. The DoH provided the university with a security project plan comprising immediate and medium-term interventions, and a commitment to execute the plan as a matter of urgency. The university’s executive management furthermore met with the management of the Faculty of Health Sciences and, based on a safety risk assessment, the university’s executive management agreed that undergraduate students could again fully access the clinical platform at Pelonomi Hospital.

Interventions in the security project plan include the installation of high-mast lights in the precinct of the hospital, reparation of the perimeter fence, security locks, and limiting access to the hospital and the hospital grounds after 20:00 until 06:00. A Venue Operation Centre (VOC) made up of SAPS, institutional security management, and the Community Policing Forum will also be established at the hospital.

“The main focus and concern for the executive management of the university is the safety of its students and staff. We are satisfied with the security plan and the overall interventions committed to by the DoH and will monitor the implementation of these interventions with the management of the Pelonomi Hospital and the DoH. The security interventions will alleviate the situation at the hospital in order for the university to continue sending its undergraduate students there for training,” said Prof Francis Petersen, UFS Rector and Vice-Chancellor, during a media briefing today.

Prof Petersen also met with undergraduate students in the Schools of Clinical Medicine, Nursing, and Allied Health Professions today to discuss the situation at the hospital. Trauma counselling is provided to undergraduate students and staff and those in need of counselling at the Pelonomi Hospital.

The DoH has furthermore extended its bus service between the clinical platforms in Bloemfontein to students in need of transport of the School of Clinical Medicine according to time slots as from the beginning of the second semester. This service will ultimately be extended to undergraduate students in the Schools of Nursing and Allied Health Professions. “We will also look into further transport solutions for the longer term for our students,” said Prof Petersen.

Undergraduate students from the university’s Schools of Clinical Medicine, Nursing, and Allied Health Professions are trained on the clinical platforms in Bloemfontein – these include the Pelonomi Hospital, Universitas Hospital, National Hospital, the Mangaung University Community Partnership Programme (MUCPP), and the Free State Psychiatric Complex.

Although these clinical training platforms are under the jurisdiction of the DoH in the Free State Province, they form a critical part of the training of undergraduate students in the university’s Faculty of Health Sciences. Staff on the joint establishment of the UFS and the DoH also work at hospitals on the clinical platforms.

Released by:
Lacea Loader (Director: Department of Communication and Marketing)
Telephone: +27 51 401 2584 | +27 83 645 2454
E-mail: news@ufs.ac.za | loaderl@ufs.ac.za

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept